215 related articles for article (PubMed ID: 29226331)
1. A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment.
Peverelli E; Giardino E; Treppiedi D; Catalano R; Mangili F; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
Int J Cancer; 2018 May; 142(9):1842-1852. PubMed ID: 29226331
[TBL] [Abstract][Full Text] [Related]
2. cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells.
Peverelli E; Giardino E; Mangili F; Treppiedi D; Catalano R; Ferrante E; Sala E; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
Cancer Lett; 2018 Oct; 435():101-109. PubMed ID: 30098401
[TBL] [Abstract][Full Text] [Related]
3. Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells.
Peverelli E; Giardino E; Treppiedi D; Vitali E; Cambiaghi V; Locatelli M; Lasio GB; Spada A; Lania AG; Mantovani G
Endocrinology; 2014 Aug; 155(8):2932-41. PubMed ID: 24828612
[TBL] [Abstract][Full Text] [Related]
4. Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells.
Treppiedi D; Mangili F; Giardino E; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Calebiro D; Mantovani G; Peverelli E
Neuroendocrinology; 2020; 110(7-8):642-652. PubMed ID: 31574507
[TBL] [Abstract][Full Text] [Related]
5. A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation.
Mangili F; Treppiedi D; Catalano R; Marra G; Di Muro G; Spada A; Arosio M; Peverelli E; Mantovani G
Front Endocrinol (Lausanne); 2020; 11():611752. PubMed ID: 33664708
[TBL] [Abstract][Full Text] [Related]
6. Dopamine receptor type 2 (DRD2) inhibits migration and invasion of human tumorous pituitary cells through ROCK-mediated cofilin inactivation.
Peverelli E; Giardino E; Treppiedi D; Locatelli M; Vaira V; Ferrero S; Bosari S; Lania AG; Spada A; Mantovani G
Cancer Lett; 2016 Oct; 381(2):279-86. PubMed ID: 27519461
[TBL] [Abstract][Full Text] [Related]
7. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells.
Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G
Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965
[TBL] [Abstract][Full Text] [Related]
8. Filamin-A is required to mediate SST2 effects in pancreatic neuroendocrine tumours.
Vitali E; Cambiaghi V; Zerbi A; Carnaghi C; Colombo P; Peverelli E; Spada A; Mantovani G; Lania AG
Endocr Relat Cancer; 2016 Mar; 23(3):181-90. PubMed ID: 26733502
[TBL] [Abstract][Full Text] [Related]
9. Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST
Treppiedi D; Marra G; Di Muro G; Catalano R; Mangili F; Esposito E; Calebiro D; Arosio M; Peverelli E; Mantovani G
Front Endocrinol (Lausanne); 2022; 13():892668. PubMed ID: 35992099
[TBL] [Abstract][Full Text] [Related]
10. Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors.
Mantovani G; Treppiedi D; Giardino E; Catalano R; Mangili F; Vercesi P; Arosio M; Spada A; Peverelli E
Endocr Relat Cancer; 2019 Feb; 26(2):R95-R108. PubMed ID: 30589642
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
12. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
[TBL] [Abstract][Full Text] [Related]
13. Filamin A in somatostatin and dopamine receptor regulation in pituitary and the role of cAMP/PKA dependent phosphorylation.
Peverelli E; Giardino E; Vitali E; Treppiedi D; Lania AG; Mantovani G
Horm Metab Res; 2014 Nov; 46(12):845-53. PubMed ID: 25068602
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Sánchez-Sánchez R; Chimelli L; Kasuki L; Luque RM; Gadelha MR
Sci Rep; 2019 Feb; 9(1):1122. PubMed ID: 30718563
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin analogs regulate tumor corticotrophs growth by reducing ERK1/2 activity.
Treppiedi D; Giardino E; Catalano R; Mangili F; Vercesi P; Sala E; Locatelli M; Arosio M; Spada A; Mantovani G; Peverelli E
Mol Cell Endocrinol; 2019 Mar; 483():31-38. PubMed ID: 30611770
[TBL] [Abstract][Full Text] [Related]
16. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
17. Single-Molecule Microscopy Reveals Dynamic FLNA Interactions Governing SSTR2 Clustering and Internalization.
Treppiedi D; Jobin ML; Peverelli E; Giardino E; Sungkaworn T; Zabel U; Arosio M; Spada A; Mantovani G; Calebiro D
Endocrinology; 2018 Aug; 159(8):2953-2965. PubMed ID: 29931263
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin (SRIF) modulates distinct signaling pathways in rat pituitary tumor cells; negative coupling of SRIF receptor subtypes 1 and 2 to arachidonic acid release.
Cervia D; Fiorini S; Pavan B; Biondi C; Bagnoli P
Naunyn Schmiedebergs Arch Pharmacol; 2002 Mar; 365(3):200-9. PubMed ID: 11882916
[TBL] [Abstract][Full Text] [Related]
19. Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation.
Giardino E; Catalano R; Barbieri AM; Treppiedi D; Mangili F; Spada A; Arosio M; Mantovani G; Peverelli E
Mol Cell Endocrinol; 2019 Sep; 495():110519. PubMed ID: 31352037
[TBL] [Abstract][Full Text] [Related]
20. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
Saveanu A; Jaquet P; Brue T; Barlier A
Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
